Effect of the solid-dispersion method on the solubility and crystalline property of tacrolimus

International Journal of Pharmaceutics

Volumn 395, Issue 1-2, 2010, Pages 161-166

  Joe, Jung Hyun ^a   Lee, Won Mo ^a   Park, Young Joon ^b   Joe, Kwan Hyung ^a,b   Oh, Dong Hoon ^a   Seo, Youn Gee ^a   Woo, Jong Soo ^a   Yong, Chul Soon ^a   Choi, Han Gon ^a  

^a Yeungnam University   (South Korea)

^b Samil Pharmaceutical Co Ltd   (South Korea)

Author keywords

Dioctyl sulfosuccinate; Hydroxypropyl cyclodextrin; Solid dispersion method; Solubility; Tacrolimus

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ALCOHOL; DICHLOROMETHANE; DIOCTYL SULFOSUCCINATE; SOLVENT; SUCCINIC ACID; TACROLIMUS; UNCLASSIFIED DRUG; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; DOCUSATE SODIUM; DRUG CARRIER; IMMUNOSUPPRESSIVE AGENT; POWDER; WATER;

ARTICLE; CRYSTAL; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG FORMULATION; DRUG SOLUBILITY; EVAPORATION; HYDROPHILICITY; HYDROPHOBICITY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPE; SOLID DISPERSION; SPRAY DRYING; WETTABILITY; X RAY DIFFRACTION; CHEMICAL PHENOMENA; CHEMISTRY; COMPARATIVE STUDY; CRYSTALLIZATION; KINETICS; MEDICINAL CHEMISTRY; PHARMACEUTICS; POWDER; POWDER DIFFRACTION; PROCEDURES; SCANNING ELECTRON MICROSCOPY; SOLUBILITY; SURFACE PROPERTY; X RAY CRYSTALLOGRAPHY;

BETA-CYCLODEXTRINS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; DIOCTYL SULFOSUCCINIC ACID; DRUG CARRIERS; DRUG COMPOUNDING; ETHANOL; HYDROPHOBICITY; IMMUNOSUPPRESSIVE AGENTS; KINETICS; METHYLENE CHLORIDE; MICROSCOPY, ELECTRON, SCANNING; POWDER DIFFRACTION; POWDERS; SOLUBILITY; SOLVENTS; SURFACE PROPERTIES; TACROLIMUS; TECHNOLOGY, PHARMACEUTICAL; WATER; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS;

EID: 77954312179     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.05.023     Document Type: Article

References (30)

1. Arima H., Yunomae K., Miyake K., Irie T., Hirayama F., Uekama K. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats. J. Pharm. Sci. 2001, 90:690-701.
2. Borhade V.B., Nair H.A., Hegde D.D. Development and characterization of self-microemulsifying drug delivery system of tacrolimus for intravenous administration. Drug Dev. Ind. Pharm. 2008, 31:1-12.
3. Borhade V., Nair H., Hegde D. Design and evaluation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus. Pharm. Sci. Technol. 2008, 9:13-21.
4. Choi H.G., Lee B.J., Yong C.S., Rhee J.D., Han J.H., Lee M.K., Park K.M., Kim C.K. Terfenadine-β-cyclodextrin inclusion complex with the anti-histaminic activity enhancement. Drug Dev. Ind. Pharm. 2001, 27:857-862.
5. Choi H.G., Oh Y.K., Kim C.K. In situ gelling and mucoadhesive liquid suppository containing acetaminophen: enhanced bioavailability. Int. J. Pharm. 1998, 165:23-32.
6. Chung Y., Cho H. Preparation of highly water soluble tacrolimus derivatives: poly(ethylene glycol) esters as potential prodrugs. Arch. Pharm. Res. 2004, 27:873-883.
7. Chutimaworapan S., Ritthidej G.C., Yonemochi E., Oguchi T., Yamamoto K. Effect of water-soluble carriers on dissolution characteristics of nifedipine solid dispersions. Drug Dev. Ind. Pharm. 2000, 26:1141-1150.
8. Craig D.Q.M. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int. J. Pharm. 2002, 231:131-144.
9. Doherty C., York P. Mechanisms of dissolution of frusemide/PVP solid dispersions. Int. J. Pharm. 1987, 34:197-205.
10. Honbo T., Kobayashi M., Hane K., Hata T., Ueda Y. The oral dosage form of FK-506. Transplant. Proc. 1987, 19:17-22.
11. Kachrimanis K., Nikolakakis I., Malamataris S. Spherical crystal agglomeration of ibuprofen by the solvent-change technique in presence of methacrylic polymers. J. Pharm. Sci. 2000, 89:250-259.
12. Khan G.M., Jiabi Z. Preparation, characterization and dissolution studies of ibuprofen solid dispersions using polyethylene glycol (PEG), talc and PEG-talc as dispersion carriers. Drug Dev. Ind. Pharm. 1998, 24:455-462.
13. Kino T., Hatanaka H., Hashimoto M., Nishiyama M., Goto T., Okuhara M., Kohsaka M., Aoki H., Imanaka N. Tacrolimus, a novel immunosuppressant isolated from Streptomyces. I. Fermentation, isolation and physicochemical and biological characteristics. J. Antibiot. 1987, 40:1249-1255.
14. Lee M.J., Straubinger R.M., Jusko W.J. Physicochemical, pharmacokinetic and pharmacodynamic evaluation of liposomal tacrolimus (FK 506) in rats. Pharm. Res. 1995, 12:1055-1059.
15. Leuner C., Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 2000, 50:47-60.
16. Li D.X., Jang K.Y., Kang W.K., Bae K.J., Lee M.H., Oh Y.K., Jee J.P., Park Y.J., Oh D.H., Seo Y.G., Kim Y.R., Kim J.O., Woo J.S., Yong C.S., Choi H.G. Enhanced solubility and bioavailability of sibutramine base by solid dispersion system with aqueous medium. Biol. Pharm. Bull. 2010, 33:279-284.
17. Li D.X., Oh Y.K., Lim S.J., Kim J.O., Yang H.J., Sung J.H., Yong C.S., Choi H.G. Novel gelatin microcapsule with bioavailability enhancement of ibuprofen using spray drying technique. Int. J. Pharm. 2008, 355:277-284.
18. Miller D.A., McConville J.T., Yang W., Williams R.O., McGinity J.W. Hot-melt extrusion for enhanced delivery of drug particles. J. Pharm. Sci. 2007, 96:361-376.
19. Moyano M.A., Simionato L.D., Pizzorno M.T., Segall A.I. Validation of a liquid chromatographic method for determination of tacrolimus in pharmaceutical dosage forms. J. AOAC Int. 2006, 89:1547-1551.
20. Nassar T., Rom A., Nyska A., Benita S. A novel nanocapsule delivery system to overcome intestinal degradation and drug transport limited absorption of P-glycoprotein substrate drugs. Pharm. Res. 2008, 25:2019-2029.
21. Newa M., Bhandari K.H., Li D.X., Kwon T.H., Kim J.A., Yoo B.K., Woo J.S., Lyoo W.S., Yong C.S., Choi H.G. Preparation, characterization and in vivo evaluation of ibuprofen binary solid dispersions with poloxamer 188. Int. J. Pharm. 2007, 343:228-237.
22. Okimoto K., Miyake M., Ibuki R., Yasumura M., Ohnishi N., Nakai T. Dissolution mechanism and rate of solid dispersion particles of nilvadipine with hydroxypropylmethylcellulose. Int. J. Pharm. 1997, 159:85-93.
23. Park Y.J., Ryu D.S., Li D.X., Quan Q.Z., Oh D.H., Kim J.O., Seo Y.G., Lee Y.I., Yong C.S., Woo J.S., Choi H.G. Physicochemical characterization of tacrolimus-loaded solid dispersion with sodium carboxylmethyl cellulose and sodium lauryl sulfate. Arch. Pharm. Res. 2009, 32:893-898.
24. Sinswat P., Overhoff K.A., McConville J.T., Johnston K.P., Williams R.O. Nebulization of nanoparticulate amorphous or crystalline tacrolimus-single-dose pharmacokinetics study in mice. Eur. J. Pharm. Biopharm. 2008, 69:1057-1066.
25. Tamura S., Ohike A., Ibuki R., Amidon G.L., Yamashita S. Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J. Pharm. Sci. 2002, 91:719-729.
26. Taylor L.S., Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm. Res. 1997, 14:1691-1698.
27. Walser S., Hruby R., Hesse E., Heinzl H., Mascher H. Preliminary toxicokinetic study with different crystal forms of S (+)-ibuprofen (dexibuprofen) and R,S-ibuprofen in rats. Arzneimittelforschung 1997, 47:750-754.
28. Watts A.B., Williams R.O., Peters J.I. Recent developments in drug delivery to prolong allograft survival in lung transplant patients. Drug Dev. Ind. Pharm. 2009, 35:259-271.
29. Yamashita K., Nakate T., Okimoto K., Ohike A., Tokunaga Y., Ibuki R., Higaki K., Kimura T. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int. J. Pharm. 2003, 267:79-91.
30. Yong C.S., Yang C.H., Rhee J.D., Lee B.J., Kim D.C., Kim D.D., Kim C.K., Choi J.S., Choi H.G. Enhanced rectal bioavailability of ibuprofen in rats by poloxamer 188 and menthol. Int. J. Pharm. 2004, 269:169-176.